Despite the absence of cytogenetic progression or ABL1 kinase mutations, our patient’s CML transformed into a rare erythroid variant, characterized by maturing erythroid precursors harboring t(9;22) BCR::ABL1. To the best of our knowledge, this is the first report of an erythroid variant transformation of CML in a patient undergoing TKI treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.